Risk Factors of Hyperammonemia in Patients With Epilepsy Under Valproic Acid Therapy
Authors:
- Chi-Ren HuangCHChi-Ren Huang
- Chih-Hsiang LinCLChih-Hsiang Lin
- Yan-Ting LuYLYan-Ting Lu
- Cheng-Hsien LuCLCheng-Hsien Lu
- Nai-Ching ChenNCNai-Ching Chen
- Chiung-Chih ChangCCChiung-Chih Chang
- Wen-Neng ChangWCWen-Neng Chang
- Yao-Chung ChuangYao-Chung Chuang
Open Access
- 1 September 2014
- journal article
- Published by Wolters Kluwer Health in Medicine
- Vol. 93 (11) , e66
Abstract
Hyperammonemia has been reported to be associated with patients who receive valproic acid (VPA) therapy. This study aimed to determine the risk factors for hyperammonemia in patients with epilepsy treated with VPA. One hundred and fifty-eight adult patients with epilepsy aged older than 17 years who received VPA therapy were enrolled into this study. Blood samples were taken during the interictal state and analyzed for the blood level of ammonia. Statistical analysis was conducted between different groups of patients. The results showed that the frequency of hyperammonemia associated with VPA therapy was 27.8% (ammonia level >93 µg/dL), and 5.1% of the patients had severe hyperammonemia (ammonia level >150 µg/dL). The blood ammonia level was significantly correlated with the dosage of VPA and the plasma concentration of VPA. An increase of 1 mg in the dosage of VPA increased the risk of hyperammonemia by 0.1%. In addition, combination treatment with liver enzyme inducing antiepileptic drugs (AEDs) and antipsychotic drugs increased the risk of hyperammonemia. In conclusion, the use of VPA in adult patients with epilepsy was associated with a dose-dependent increase in blood concentrations of ammonia. Combination treatment with liver enzyme-inducing AEDs and antipsychotic drugs increased the risk of VPA-induced hyperammonemia. Most of the patients with VPA-induced hyperammonemia were asymptomatic; however, if patients taking VPA present with symptoms such as nausea, fatigue, somnolence, ataxia, and consciousness disturbance, the blood ammonia level should be measured.Keywords
This publication has 32 references indexed in Scilit:
- Risk factors for hyperammonemia in pediatric patients with epilepsyEpilepsia, 2013
- Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patientsEpilepsy Research, 2012
- New insights on the mechanisms of valproate-induced hyperammonemia: Inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoAJournal of Hepatology, 2011
- Hyperammonemia in review: pathophysiology, diagnosis, and treatmentPediatric Nephrology, 2011
- The real mechanism of VPA-induced hyperammonemia remains unknownGeneral Hospital Psychiatry, 2010
- The measurement of ammonia blood levels in patients taking valproic acid: Looking for problems where they do not exist?Epilepsy & Behavior, 2008
- Side effects of valproateThe American Journal of Medicine, 1988
- Blood Ammonia Level during Valproic Acid TherapyPsychiatry and Clinical Neurosciences, 1986
- Chronic Valproic Acid Therapy and Incidence of Increases in Venous Plasma AmmoniaTherapeutic Drug Monitoring, 1985
- Asymptomatic Hyperammonemia in Patients Receiving Valproic AcidArchives of Neurology, 1982